dulaglutide vs semaglutide Impact of patient characteristics on efficacy and safety of once-weekly versus dulaglutide: SUSTAIN 7 post hoc analyses Which GLP-1 agonist drugs have

Retatrutide is not yet available in the UK, with phase III trial results expected in 2026

Individual results vary based on clinical eligibility, prescribed treatment, adherence, and personal health factors

Watch Four Corners' The Ozempic Underground on ABC iview

Search MORE TO EXPLORE Get expert insights and real-world perspectives from leading voices in the industry to help you make more informed decisions

Consistent use combined with balanced eating habits can lead to more meaningful progress

Europe Market Insight : In Europe, there is an increasing interest in metabolic health and weight management, with GLP-1 boosters gaining popularity for their potential to support insulin sensitivity